Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2012 August;103(4) > Minerva Medica 2012 August;103(4):267-78

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

  TARGETING: RENAL DISEASES


Minerva Medica 2012 August;103(4):267-78

language: English

A primer on the epigenetics of kidney fibrosis

Mahl Tampe D., Zeisberg M.

Department of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Göttingen, Germany


PDF  


Despite extensive knowledge of the various molecular pathways that contribute to tubulointerstitial fibrosis, it remains an unsolved question why the progression rate of chronic kidney disease varies substantially from patient to patient, even among patients with common underlying nephropathies and comorbidities. Possible explanations for different susceptibilities of individual patients to develop end-stage renal failure include genetic or epigenetic variations, which modify how individual patients respond to kidney injury. Here we review principles of epigenetic mechanisms in context of chronic kidney disease and discuss how such insights may be utilized for future therapeutic strategies and may lead to novel diagnostic tools in the future.

top of page

Publication History

Cite this article as

Corresponding author e-mail

mzeisberg@med.uni-goettingen.de